Skip to Main Content

Christi Shaw, the CEO of Gilead’s Kite Pharmaceuticals cell therapy unit, is leaving the company, Gilead said Friday in a statement.

Shaw, who took the Kite role in July 2019, had previously said that she was inspired to take the role in part by the experience of watching her sister fight cancer. Under her leadership, the once-embattled division, which makes personalized CAR-T treatments for blood cancers, has begun to be a significant contributor to Gilead’s overall business.


Shaw is leaving at the end of March. Gilead is conducting a search for her replacement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.